Urothelial carcinoma

Merseburger, Axel S.; Shariat, Shahrokh F.

doi:10.1007/s00345-011-0733-9

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urothelial carcinoma is the fourth most frequently diagnosed malignancy in the United States, with a projected incidence of 70 530 new cases and 14 680 deaths in 2010. 1 Most of these tumors are located in the lower urinary tract, with bladder as the primary location and urothelial as the major histologic type. Upper urinary tract tumors are relatively infrequent and account for no more than 5% of urinary neoplasms, with an estimated annual incidence of 1.2 cases/100 000 inhabitants in Europe.…”

Section: Introductionmentioning

confidence: 99%

Primary Ureteral Thyroid Transcription Factor 1–Positive Small Cell Neuroendocrine Carcinoma

et al. 2015

View full text Add to dashboard Cite

Upper urinary tract neoplasms comprise only 5% of urinary malignancies overall, the overwhelming majority showing an urothelial histology. Nonurothelial lesions represent 1.9% of upper tract neoplasms, and small cell carcinomas (SmCCs) only account for a minute fraction of them, with few cases reported in the literature to date. In the genitourinary tract, these lesions are most frequently found in the urinary bladder, where they tend to show a mixed histology with a characteristic small cell neuroendocrine component that is positive for chromogranin A, synaptophysin, and CD56 immunostains. Urinary SmCCs are almost invariably aggressive, with a propensity to infiltrate surrounding tissues and vascular structures. Unfortunately, clinical stage at presentation is often advanced, with early dissemination to lymph nodes or distant organs in a significant proportion of patients. For the most part, prognosis is dismal and can be predicted by the pathologic stage at diagnosis. Recently, new chemotherapeutic regimens have shown some potential benefit for the treatment of urinary SmCC, albeit not achieving curative results. Here we present the case of a 71-year-old male patient with a history of treated bladder urothelial carcinoma that presented with subacute flank pain and was diagnosed with a primary pure SmCC of the ureter. Besides the usual neuroendocrine immunomarkers, this tumor showed intense positivity for TTF-1 (thyroid transcription factor-1), a phenomenon that has been described for extrapulmonary SmCC of other locations.

show abstract

Section: Introductionmentioning

confidence: 99%